Theramex

Theramex is a pharmaceutical company based in London which produces women's health products focusing on contraception, fertility, menopause and osteoporosis.

It was established in 2018 with the acquisition of some of the assets of Teva Active Pharmaceutical Ingredients relating to Theramex Laboratories, a pharmaceutical company which was based in Monaco. Brands include Ovaleap, Zoely, Seasonique, Actonel, Estreva and Lutenyl.[1]

Anish Mehta is the chief executive.

In the latter part of 2018 there were problems with the production of its hormone replacement therapy products Evorel, FemSeven Conti and FemSeven Sequi.[2] These Hormone replacement therapy patches were not available because of issues manufacturing the glue for the patches in China.[3] The company recruited another manufacturer to assist with supply in December 2019. [4] It is not expected that normal supplies will be available before June 2020.[5]

It made an agreement with TherapeuticsMD in 2019 for exclusive licensing and supply rights to Bijuva and Imvexxy outside of the USA, for which it paid a license fee of $15.5 million.[6]


References
  1. "New pharma company dedicated to women and their health launches". European Pharmaceutical Manufacturer. 5 February 2018. Retrieved 23 February 2020.
  2. "Shortage of HRTs FemSeven Conti and Sequi to continue until 2020". Chemist & Druggist. 30 April 2019. Retrieved 23 February 2020.
  3. "HRT drugs rationed amid UK shortage set to last for months". Telegraph. 24 August 2019. Retrieved 23 February 2020.
  4. "HRT products to return earlier than expected". Pharmaceutical Journal. 11 December 2019. Retrieved 23 February 2020.
  5. "The HRT crisis that forces women to buy online". Telegraph. 11 February 2020. Retrieved 23 February 2020.
  6. "Is TherapeuticsMD Stock a Buy?". The Motley Fool. 13 February 2020. Retrieved 23 February 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.